Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSHR | P23945 | 12/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2195596 | 0.87 | FSHR (0.78) | FSHRTSHRMAPT | |
| SCHEMBL3655121 | 0.78 | FSHR (0.62) | FSHRTSHRMAPT | |
| SCHEMBL1323766 | 0.73 | FSHR (0.71) | FSHRTSHRMEN1KMT2A | |
| SCHEMBL2192026 | 0.73 | TSHR (0.68) | FSHRTSHR | |
| SCHEMBL2193480 | 0.72 | TSHR (0.65) | FSHRTSHRMAPT | |
| SCHEMBL2192728 | 0.72 | FSHR (0.65) | FSHRTSHRMEN1KMT2A | |
| SCHEMBL2191283 | 0.72 | FSHR (0.56) | FSHRTSHRMAPT | |
| SCHEMBL28279154 | 0.70 | MAPT (0.73) | MEN1MAPTKMT2A | |
| SCHEMBL2193680 | 0.70 | TSHR (1.00) | FSHRTSHR | |
| SCHEMBL2192031 | 0.70 | TSHR (0.59) | FSHRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174940-B2 | TSH receptor antagonizing tetrahydroquinoline compounds | MERCK SHARP & DOHME B.V. (NL) | 2015-11-03 | — | — | US | claimed |
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | N.V. ORGANON | 2011-07-14 | — | — | US | claimed |
| EP-2197445-B1 | TSH RECEPTOR ANTAGONIZING TETRAHYDROQUINOLINE COMPOUNDS | MERCK SHARP & DOHME (NL) | 2017-04-19 | — | — | EP | disclosed |
| US-9174940-B2 | TSH receptor antagonizing tetrahydroquinoline compounds | MERCK SHARP & DOHME B.V. (NL) | 2015-11-03 | — | — | US | disclosed |
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | N.V. ORGANON | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | TSHR, MC1R, TRHR | FSHR 21/4885TSHR 1/4885MEN1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.